NeoStem, Inc. Awarded NIH Research and Research Infrastructure 'Grand Opportunit...(e technologies and new approaches to imp...)

Date:10/6/2009

e technologies, and new approaches to improve the synergy and interactions among multi and interdisciplinary research teams. The program is intended for research activities that have high, short-term impact, and a high likelihood of enabling growth and investment in biomedical research and development in new fields of investigation. "We are gratified to receive this funding from NIH," said Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer. "Our broad range of clinical research activities supports our novel approach to characterizing adult pluripotent stem cells taken from peripheral blood. We believe that our VESL technology will emerge as a competitive differentiator that will put us at the forefront of advances with autologous adult stem cell therapies in the field of regenerative medicine."

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press re
'/>"/>

SOURCE NeoStem, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
2. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
3. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
4. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
5. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
6. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
7. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
8. Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
9. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
10. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
11. Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness